Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models

With these strong preclinical results, Inovio plans to initiate a phase I/IIa clinical trial next year.

http://www.biospace.com/news_story.aspx?StoryID=306013&full=1